10/11/2010

Orion invites analysts and media to Q3 news conference on Tuesday 26 October 2010

ORION CORPORATION     STOCK EXCHANGE RELEASE           11 OCTOBER at 11.30 AM EEST

 

Orion will publish its Interim Report January-September 2010 on Tuesday, 26 October 2010 approximately at 12:00 Finnish time (EEST). The release and related presentation material in Finnish and in English will be available on the Group's homepage at www.orion.fi/en promptly after the publishing.

 

News conference for analysts and media on Tuesday 26 October 2010 at 14:30 EEST

A news conference for analysts and media on the Q3 result will be held on Tuesday 26 October 2010 at 14:30 EEST at Hotel Kämp, address Pohjoisesplanadi 29, Helsinki. President and CEO Timo Lappalainen will give a brief presentation in English on the financial review.

 

Live webcast and conference call

The event can be followed live as a webcast accessible at www.orion.fi/en. Questions can be asked also through conference call lines after the result presentation.

 

The conference call ID is 877,537 and the phone numbers to participate the conference are:
when calling from the United States +1 888 222 0364
when calling from other countries +44 (0)20 7162 0125

 

News conference recordings

A recording of the event in English will be available later the same day via a link on the Orion website. A recording of the presentation by the President and CEO in Finnish will be available on the Orion website later the same day.

 

Silent period

The silent period preceding the publication of the Q3 report is ongoing and continues until the disclosure.

 

 

 

Orion Corporation

 

 

 

Timo Lappalainen
President and CEO
Jari Karlson
CFO

 

 

Publisher:
Orion Corporation
www.orion.fi/en

 

Orion is an innovative European R&D-based pharmaceutical and diagnostic company with a special emphasis on developing medicinal treatments and diagnostic tests for global markets. Orion develops, manufactures and markets human and veterinary pharmaceuticals, active pharmaceutical ingredients and diagnostic tests. Orion's pharmaceutical R&D focuses on the following core therapy areas: central nervous system drugs, cancer and critical care drugs, and Easyhaler® pulmonary drugs.

 

The Group's net sales in 2009 amounted to EUR 772 million. The Company invested EUR 95 million in research and development. At the end of 2009, the Group had a total of 3,100 employees, of whom 2,500 worked in Finland and 600 in other European countries. Orion's A and B shares are listed on NASDAQ OMX Helsinki.